Working… Menu

A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02094365
Recruitment Status : Completed
First Posted : March 21, 2014
Last Update Posted : December 23, 2014
Information provided by (Responsible Party):
Alios Biopharma Inc.

Brief Summary:
This study is designed to compare the antiviral effect of ALS-008176 compared to a placebo control in the respiratory syncytial virus challenge model.

Condition or disease Intervention/treatment Phase
Respiratory Syncytial Virus Infections Drug: ALS-008176 Drug: vehicle Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model
Study Start Date : March 2014
Actual Primary Completion Date : June 2014
Actual Study Completion Date : July 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ALS-008176
ALS-008176 drug substance for oral suspension
Drug: ALS-008176
Placebo Comparator: vehicle alone
Vehicle alone
Drug: vehicle

Primary Outcome Measures :
  1. Change in viral load measurements. [ Time Frame: Baseline to day 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 18 to 45 years, inclusive.
  • In good health with no history of major medical conditions
  • A total body weight ≥ 50 kg and a body mass index (BMI) of > 18kg/m2.

Exclusion Criteria:

  • Acute or chronic medical illness
  • Positive for Human Immunodeficiency Virus, Hepatitis B or C
  • Nose or nasopharynx abnormalities
  • Abnormal lung function

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02094365

Layout table for location information
United Kingdom
Retroscreen Virology Ltd
London, United Kingdom
Sponsors and Collaborators
Alios Biopharma Inc.
Layout table for investigator information
Principal Investigator: Hosnieh Fathi, MD, MSc Retroscreen Virology Ltd.

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Alios Biopharma Inc. Identifier: NCT02094365     History of Changes
Other Study ID Numbers: ALS-8176-502
First Posted: March 21, 2014    Key Record Dates
Last Update Posted: December 23, 2014
Last Verified: March 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Syncytial Virus Infections
Virus Diseases
Pneumovirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections